Cheng Shih-Lung, Lin Ching-Hsiung, Yao Chao-Ling
Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan; Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li District, Taoyuan City, Taiwan.
Division of Chest Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Stem Cells Int. 2017;2017:8916570. doi: 10.1155/2017/8916570. Epub 2017 Feb 20.
Patients with chronic obstructive pulmonary disease (COPD) have chronic, irreversible airway inflammation; currently, there is no effective or curative treatment and the main goals of COPD management are to mitigate symptoms and improve patients' quality of life. Stem cell based therapy offers a promising therapeutic approach that has shown potential in diverse degenerative lung diseases. Preclinical studies have demonstrated encouraging outcomes of mesenchymal stem/stromal cells (MSCs) therapy for lung disorders including emphysema, bronchopulmonary dysplasia, fibrosis, and acute respiratory distress syndrome. This review summarizes available data on 15 studies currently registered by the ClinicalTrials.gov repository, which used different stem cell therapy protocols for COPD; these included bone marrow mononuclear cells (BMMCs), bone marrow-derived MSCs, adipose-derived stem/stromal cells (ADSCs), and adipose-derived MSCs. Published results of three trials indicate that administering BMMCs or MSCs in the setting of degenerative lung disease is safe and may improve patients' condition and quality of life; however, larger-scale studies are needed to evaluate efficacy. Results of another completed trial (NCT01872624) are not yet published, and eleven other studies are ongoing; these include MSCs therapy in emphysema, several studies of ADSCs in COPD, another in idiopathic pulmonary fibrosis, and plerixafor mobilization of CD117 stem cells to peripheral blood.
慢性阻塞性肺疾病（COPD）患者存在慢性、不可逆的气道炎症；目前，尚无有效的治愈性治疗方法，COPD管理的主要目标是减轻症状并改善患者的生活质量。基于干细胞的疗法提供了一种有前景的治疗方法，已在多种退行性肺病中显示出潜力。临床前研究已证明间充质干细胞（MSCs）疗法对包括肺气肿、支气管肺发育不良、纤维化和急性呼吸窘迫综合征在内的肺部疾病具有令人鼓舞的效果。本综述总结了ClinicalTrials.gov数据库目前登记的15项研究的现有数据，这些研究针对COPD采用了不同的干细胞治疗方案；其中包括骨髓单个核细胞（BMMCs）、骨髓来源的MSCs、脂肪来源的干/基质细胞（ADSCs）和脂肪来源的MSCs。三项试验的已发表结果表明，在退行性肺病患者中给予BMMCs或MSCs是安全的，可能改善患者的病情和生活质量；然而，需要更大规模的研究来评估疗效。另一项已完成试验（NCT01872624）的结果尚未发表，其他11项研究正在进行中；其中包括肺气肿的MSCs疗法、多项ADSCs治疗COPD的研究、另一项针对特发性肺纤维化的研究以及普乐沙福动员CD117干细胞至外周血的研究。
